Nexvet picks up biologics plant in Ireland

Ireland's low taxes and generosity with incentives have been a big draw to makers of drugs for humans which have built and bought plants there. But veterinary biologics developer Nexvet Biopharma ($NVET) says it has been enticed as well. With help from the IDA, Nextvet subsidiary BioNua will establish a biologics plant in Tullamore and create up to 30 new jobs. It is paying €1.75 million ($1.98 million) to secure the manufacturing assets in a facility once used by Reliance GeneMedix. It will lease the facility for 10 years. Release

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.